VREX

Rating neutralAI MemoPost-earnings T+1

Varex Imaging

As of 2026-05-08/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Fiscal Q2 results were in range, but the market is reacting to softer profitability and only modest second-half growth guidance • 2026-05-08

Base target: $11 / p=1% prob

Biggest risk

The bearish read is that profitability and cash conversion remain weak: Q2 non-GAAP gross margin fell to 34%, GAAP EPS was a loss of $0.19, first-half operating cash flow was negative $17.6 million, inventories rose materially, and the stock's sharp May 8, 2026 selloff suggests investors are not yet willing to underwrite a clean second-half recovery.

Invalidation

Break below $9 or thesis failure.

What would change my mind?

The constructive read is that Varex delivered revenue within its prior range, cited solid demand in CT, cargo systems, and photon counting detectors, and guided to second-half fiscal 2026 year-over-year growth despite excluding any IEEPA tariff refund from guidance. The March refinancing also removed the nearer-term 2027 note maturity overhang, which helps if operations firm from here.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-08

Base target

$11

p=1%

Bull target

$15

p=0%

Bear target

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q3 guidance becomes the next near-term test, with no IEEPA tariff refund assumed
Backlog and second-half demand can help the stock recover only if inventory converts to cash and margins stabilize
The constructive read is that Varex delivered revenue within its prior range, cited solid demand in CT, cargo systems, and photon counting detectors, and guided to second-half fiscal 2026 year-over-year growth despite excluding any IEEPA tariff refund from guidance.

BearKey bullets

Cash generation remains weak, with first-half operating cash flow negative $17.6 million and quarter-end cash, cash equivalents, and marketable securities down to $88.3 million from $155.1 million at fiscal year-end.
[#10-Q-2026-05-07]
Customer concentration remains meaningful: one customer represented 19% of quarterly revenue and the top ten customers represented about 52% of quarterly revenue.

WatchKey bullets

Fiscal Q2 results were in range, but the market is reacting to softer profitability and only modest second-half growth guidance

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $11 (p=1%)

Target spread vs base: +32% / -23%

Scenario probabilities

Bull Target: $15 (p=0%)Base Target: $11 (p=1%)Bear Target: $9 (p=0%)

Commentary

This is a T+1 post-earnings monitoring setup, not a clean bullish reset. Primary-source evidence is solid, but the new information mostly confirms a mixed print: in-range revenue, softer margins, weak cash conversion, and modest second-half growth guidance. Immediate market reaction was negative, with VREX trading at $9.73 on May 8, 2026 versus the May 7, 2026 anchor close of $11.83, and trustworthy analyst revision detail was still unavailable at this stage.

As of 2026-05-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q3 guidance becomes the next near-term test, with no IEEPA tariff refund assumed
Backlog and second-half demand can help the stock recover only if inventory converts to cash and margins stabilize

Scenarios

Bull Target (Scenario probability)

$15 / p=0% prob

Base Target (Scenario probability)

$11 / p=1% prob

Bear Target (Scenario probability)

$9 / p=0% prob

Analysis 2026-05-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-08
Fiscal Q2 results were in range, but the market is reacting to softer profitability and only modest second-half growth guidance
Varex reported fiscal Q2 revenue of $216.0 million, non-GAAP EPS of $0.21, and cash outflow from operations of $2 million. Management said demand remained solid across CT, cargo systems, and photon counting detectors, but non-GAAP gross margin fell to 34% from 36% a year earlier and full-year guidance of $860 million-$880 million revenue with $0.80-$1.00 non-GAAP EPS still leaves limited room for execution misses. The May 8, 2026 market reaction was sharply negative, with shares trading at $9.73 versus the May 7, 2026 anchor close of $11.83. [#8-K-2026-05-07]
Prob 85.00% • Move 14.00% • Priced-in 72.00%

Short-term Catalysts

Next few weeks

Q3 guidance becomes the next near-term test, with no IEEPA tariff refund assumed
2026-08-01
For fiscal Q3 2026, Varex guided to revenue of $210 million-$225 million and non-GAAP EPS of $0.15-$0.30, while explicitly stating that no IEEPA tariff refund is assumed in guidance. That keeps the near-term setup tied to whether demand in Medical and Industrial can offset material-cost pressure and tariff uncertainty. [#8-K-2026-05-07]
Prob 66% • Move 11% • Priced-in 58%

Long-term Catalysts

Months to a year

Backlog and second-half demand can help the stock recover only if inventory converts to cash and margins stabilize
2026-09-30
The 10-Q showed estimated backlog of about $266 million at April 3, 2026, while inventories rose to $346.7 million from $299.4 million at fiscal year-end and operating cash flow for the first six months was negative $17.6 million. Management said second-half fiscal 2026 revenue should be up about 3% year over year, but the longer thesis still depends on turning anticipated demand into shipments, cash generation, and better gross-margin performance. [#10-Q-2026-05-07] [#8-K-2026-05-07]
Prob 52% • Move 20% • Priced-in 33%

Risks

Cash generation remains weak, with first-half operating cash flow negative $17.6 million and quarter-end cash, cash equivalents, and marketable securities down to $88.3 million from $155.1 million at fiscal year-end. [#10-Q-2026-05-07]
Customer concentration remains meaningful: one customer represented 19% of quarterly revenue and the top ten customers represented about 52% of quarterly revenue. [#10-Q-2026-05-07]
Gross-margin pressure persisted, with total gross margin falling to 33.6% in the 10-Q and non-GAAP gross margin at 34% in the earnings release. [#10-Q-2026-05-07] [#8-K-2026-05-07]
Inventory built to support anticipated demand, but that raises order-conversion and working-capital risk if customer timing slips. [#10-Q-2026-05-07]
Tariff and trade-policy risk remains live, and management explicitly excluded any IEEPA tariff refund from guidance. [#8-K-2026-05-07]

Peers

Symbol	Summary
CERS	Cerus is a closer small-cap healthcare equipment peer by size, but its transfusion-safety exposure is less cyclical than Varex's imaging-components and cargo-security mix, so VREX carries more margin and order-conversion risk around hospital and industrial demand.
BBNX	Beta Bionics is another smaller-cap healthcare equipment name, but it is not an operating imaging peer; the comparison mainly highlights that VREX trades with a higher balance-sheet and manufacturing-cycle sensitivity than many same-sector device stocks.
ABT	Abbott is a broad medtech benchmark rather than a direct peer, and its scale, diversification, and stronger balance sheet underline why VREX should retain a discount until inventory, cash flow, and margin recovery are more visible.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-08

Loading AI feed…

Symbol

Summary

CERS

Cerus is a closer small-cap healthcare equipment peer by size, but its transfusion-safety exposure is less cyclical than Varex's imaging-components and cargo-security mix, so VREX carries more margin and order-conversion risk around hospital and industrial demand.

BBNX

Beta Bionics is another smaller-cap healthcare equipment name, but it is not an operating imaging peer; the comparison mainly highlights that VREX trades with a higher balance-sheet and manufacturing-cycle sensitivity than many same-sector device stocks.

ABT

Abbott is a broad medtech benchmark rather than a direct peer, and its scale, diversification, and stronger balance sheet underline why VREX should retain a discount until inventory, cash flow, and margin recovery are more visible.